Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial

article








Wit, J. de

Totté, J.E.E.

Mierlo, M.M.F. van

Veldhuizen, J. van

Doorn, M.B.A. van

Schuren, F.H.J.

Willemsen, S.P.

Pardo, L.M.

Pasmans, S.G.M.A.
Letter to the editor. Staphylococcus aureus density is increased in many patients with atopic dermatitis (AD) and is thought to contribute to disease pathogenesis, interacting with an altered skin barrier and immunologic changes.1 S aureus might induce or aggravate inflammation through different mechanisms, for example through excretion of virulence factors, even if the S aureus overgrowth is primarily caused by other factors.2 Current guidelines only recommend antimicrobial therapy directed against S aureus in patients with clinically infected AD based on a Cochrane review in which no clinical benefit of short-term antimicrobial treatment in patients with noninfected AD was found.
TNO Identifier
867949
Repository link
https://resolver.tno.nl/uuid:83764f31-7c0b-4dae-8e2b-0d937e3dff19
ISSN
916749
Source
Journal of Allergy and Clinical Immunology, 144(3), pp. 860-863.
Pages
860-863
Files
To receive the publication files, please send an e-mail request to TNO Repository.